Coloray International Investment Past Earnings Performance
Past criteria checks 0/6
Coloray International Investment's earnings have been declining at an average annual rate of -24.1%, while the Chemicals industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 5.2% per year. Coloray International Investment's return on equity is 0.6%, and it has net margins of 3.1%.
Key information
-24.1%
Earnings growth rate
-24.6%
EPS growth rate
| Chemicals Industry Growth | 13.9% |
| Revenue growth rate | -5.2% |
| Return on equity | 0.6% |
| Net Margin | 3.1% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Coloray International Investment (KOSDAQ:900310) Will Want To Turn Around Its Return Trends
Oct 14
Weak Statutory Earnings May Not Tell The Whole Story For Coloray International Investment (KOSDAQ:900310)
Jun 06Returns On Capital At Coloray International Investment (KOSDAQ:900310) Paint A Concerning Picture
Jun 04What Do The Returns On Capital At Coloray International Investment (KOSDAQ:900310) Tell Us?
Mar 03Should You Use Coloray International Investment's (KOSDAQ:900310) Statutory Earnings To Analyse It?
Feb 03How Much Did Coloray International Investment's(KOSDAQ:900310) Shareholders Earn From Share Price Movements Over The Last Three Years?
Jan 06
Do Insiders Own Lots Of Shares In Coloray International Investment Co., Ltd. (KOSDAQ:900310)?
Dec 10The Trends At Coloray International Investment (KOSDAQ:900310) That You Should Know About
Nov 19Revenue & Expenses Breakdown
How Coloray International Investment makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 49,825 | 1,541 | 5,832 | 1,854 |
| 31 Mar 24 | 47,066 | 3,314 | 5,693 | 1,854 |
| 31 Dec 23 | 46,428 | 5,319 | 5,763 | 1,565 |
| 30 Sep 23 | 41,177 | 12,241 | 4,351 | 1,130 |
| 30 Jun 23 | 42,699 | 13,210 | 4,267 | 1,130 |
| 31 Mar 23 | 39,734 | 9,956 | 3,428 | 1,591 |
| 31 Dec 22 | 38,856 | 11,599 | 2,842 | 2,145 |
| 30 Sep 22 | 45,993 | 16,244 | 3,235 | 2,496 |
| 30 Jun 22 | 45,887 | 19,427 | 2,682 | 2,496 |
| 31 Mar 22 | 58,854 | 25,234 | 2,988 | 2,346 |
| 31 Dec 21 | 60,910 | 26,198 | 3,799 | 1,841 |
| 30 Sep 21 | 69,943 | 24,292 | 4,362 | 1,225 |
| 30 Jun 21 | 72,333 | 21,496 | 5,129 | 1,225 |
| 31 Mar 21 | 73,375 | 21,661 | 5,447 | 1,184 |
| 31 Dec 20 | 73,738 | 22,055 | 5,110 | 1,591 |
| 30 Sep 20 | 55,355 | 19,424 | 4,864 | 1,788 |
| 30 Jun 20 | 52,265 | 22,757 | 4,424 | 1,788 |
| 31 Mar 20 | 48,449 | 23,330 | 3,779 | 1,868 |
| 31 Dec 19 | 50,861 | 24,200 | 4,309 | 1,549 |
| 30 Sep 19 | 50,082 | 25,397 | 3,589 | 1,305 |
| 30 Jun 19 | 48,932 | 24,664 | 4,379 | 1,305 |
| 31 Mar 19 | 48,696 | 27,023 | 4,274 | 1,392 |
| 31 Dec 18 | 48,244 | 26,454 | 3,818 | 2,196 |
| 30 Sep 18 | 49,950 | 26,933 | 3,852 | 2,506 |
| 30 Jun 18 | 50,702 | 27,388 | 3,546 | 2,506 |
| 31 Mar 18 | 47,168 | 22,386 | 3,364 | 2,634 |
| 31 Dec 17 | 47,727 | 23,690 | 3,707 | 2,111 |
| 30 Sep 17 | 48,938 | 24,727 | 3,775 | 1,894 |
| 30 Jun 17 | 46,828 | 23,708 | 2,491 | 2,265 |
| 31 Mar 17 | 43,154 | 21,835 | 2,076 | 2,029 |
| 31 Dec 16 | 39,024 | 19,271 | 2,400 | 1,420 |
| 30 Jun 16 | 29,253 | 13,162 | 1,364 | 1,077 |
| 31 Dec 15 | 27,801 | 11,027 | 1,209 | 1,097 |
Quality Earnings: A900310 has a large one-off gain of ₩1.4B impacting its last 12 months of financial results to 30th June, 2024.
Growing Profit Margin: A900310's current net profit margins (3.1%) are lower than last year (30.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A900310's earnings have declined by 24.1% per year over the past 5 years.
Accelerating Growth: A900310's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: A900310 had negative earnings growth (-88.3%) over the past year, making it difficult to compare to the Chemicals industry average (-4.5%).
Return on Equity
High ROE: A900310's Return on Equity (0.6%) is considered low.